secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001140361-23-058160
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics refinances with $135M Ares facility, repays $159M Hayfin debt, reduces debt 15%
--------------------------------------------------------------------------------

- New $135M senior secured credit facility ($72.5M revolver + $62.5M term loan) fully drawn to repay prior Hayfin debt.
- Total debt reduced 15% from $159M to $135M; 4-year interest-only maturity (Dec 2027).
- Term loan initial rate SOFR+6.50% (11.88%); revolver initial rate SOFR+3.75% (9.13%), lower than prior facility.
- Proceeds used to terminate Hayfin credit facility; cash on hand contributed to payoff.
- CEO states transaction is non-dilutive and supports earnings growth; Ares Management credit funds provide financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123058160/0001140361-23-058160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123058160/ef20016811_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-058160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer